Development of mPGES-1 inhibitors for treatment of inflammatory pain
Our laboratory has been involved in a long-term collaboration project with Swedish company BIOLIPOXaimed at the development of a medication for treatment of inflammatory pain, such as from rheumatoid arthritis.
The goal of the project was design of selective inhibitor of membrane-bound prostaglandin (PG) E synthase (mPGES-1), an enzyme necessary for the production of Prostaglandin E2 (PGE2).
In 2010, a candidate drug for further clinical development has been selected (OREXO press-release).